drugset / Trial / NCT00406575
Recombinant Human Relaxin for the Treatment of Decompensated CHF
Phase 2
Terminated
11 enrolled
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
RandomizedParallel-groupDouble-blindTreatment
Summary
Two doses of relaxin will be compared to placebo for the treatment of patients with decompensated CHF
Timeline
- Start
- 2006-11
- Primary completion
- 2007-01
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Serelaxin | Protein / enzyme biologic | 100 ug/kg | Intravenous |
| Subject | Serelaxin | Protein / enzyme biologic | 500 ug/kg | Intravenous |